Skip to content
2000
Volume 12, Issue 2
  • ISSN: 1574-8863
  • E-ISSN: 2212-3911

Abstract

Introduction: Thalidomide, previously banned owing to the issues of teratogenicity is being used and tested for a variety of dermatological and non dermatological conditions. The drug has been approved for the management of erythema nodosum leprosum [ENL] and multiple myeloma [MM]. The drug is commonly known to produce adverse effects like peripheral neuropathy and constipation. Deep vein thrombosis [DVT] is one of the serious adverse effects seen with thalidomide use, especially in malignancies and is relatively uncommon in non cancer settings like ENL. Method: Here we report a case of DVT occurring after 8 months of use of thalidomide in a young patient of 22 years age suffering from ENL. Result: The case highlights the problems faced in the management of refractory ENL and the treatment of DVT in the setting of multiple drug interactions and financial constraints. Conclusion: New guidelines are required regarding the prophylaxis and management of DVT associated with thalidomide use in non-malignant conditions.

Loading

Article metrics loading...

/content/journals/cds/10.2174/1574886312666170518153225
2017-07-01
2025-09-04
Loading full text...

Full text loading...

/content/journals/cds/10.2174/1574886312666170518153225
Loading

  • Article Type:
    Research Article
Keyword(s): azathioprine; DVT; ENL; Hansen' disease; pharmacovigilance; thalidomide
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test